Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EX-054
- Development stage
- Preclinical
- Lead developer
- Excelsior
- Modality
- Gene Therapies
01
Overview
EX-054 is an investigational gene therapy candidate currently in the preclinical stage of development by Excelsior (Excelsior Group). The program is managed by the company's Asia-Pacific Special Disease Research Center. While the specific genetic target and the exact nature of the "Asia-Pacific Special Disease" (亞太特殊疾病) have not been publicly disclosed, the program focuses on utilizing gene therapy modalities to address regional health needs in the Asia-Pacific area.
- Other names
- EX-054 gene therapyEX054 gene therapyEX 054 gene therapy
Beyond the preview
Go deeper on EX-054.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EX-054.